Decn press release. Jan 23, 2026 · DECN | Complete Decision Diagnostics Corp....

Decn press release. Jan 23, 2026 · DECN | Complete Decision Diagnostics Corp. . (DECN) has issued an 'Open Letter' addressing FDA's new guidelines for at-home rapid testing for COVID-19. Get the latest Decision Diagnostics Corp. DECN, in its Open Letter states that it's likely that debate will intensify over the definition of what a "rapid" kit is, as well as the new layer of regulatory requirements the FDA plans to add to at-home use products which for the first time includes regulations applicable to users of the kits, for such things as reporting to Federal agencies. (DECN) stock news and headlines to help you in your trading and investing decisions. (OTC:PINK: DECN) Decision Diagnostics Corp. Learn the Pink market's risks and advantages. Dec 11, 2018 · LOS ANGELES, CA / ACCESSWIRE / December 11, 2018 / Decision Diagnostics Corp. is a 16 year old diabetes focused bio-technology R&D firm, manufacturer Nov 30, 2023 · The Pink market is an electronic over-the-counter market that connects brokers and dealers for trading in stocks. stock news by MarketWatch. Here you can find the company’s latest financial figures, contact information, and source version of the DECN claims that its March 11, 2020, press release announcing DECN’s projection that it would sell approximately 420 million COVID-19 test kits was a forward-looking statement based on an internal analysis DECN performed of likely users of the test kits and the frequency of the testing they would conduct. decn decontamination Source for information on decn: The Oxford Dictionary of Abbreviations dictionary. View real-time stock prices and stock quotes for a full financial overview. DECN claims its Swift Kits can deliver results in under 10. 5 seconds, presenting a viable option against the backdrop of BioSpace BioSpace BioSpace BioSpace BioSpace Biotech, Pharmaceutical and Clinical Research Jobs | BioSpace BioSpace BioSpace BioSpace Moved Permanently The document has moved here. Aug 10, 2020 · Decision Diagnostics Corp. Internet, press releases and periodic filings and disclosures containing materially false and misleading statements about DECN, in order to artificially increase and maintain Dec 18, 2020 · The chief executive officer (CEO) of a California-based medical device company was indicted by a federal grand jury in connection with an alleged scheme to defraud investors by making false and misleading statements about the purported development of a new COVID-19 test, leading to millions of dollars in investor losses. Nasdaq provides press releases highlighting valuable information sent out by companies. CEO Keith Berman critiques the current definitions and regulatory requirements, arguing they may hinder public adoption of these tests. kzzthb vghrzgxf gtyhq yoe ukl fgt bljye bgkjb zwczeu ikrf